Who founded Helus Pharma?

Helus Pharma was founded by Eric So, John Kanakis, Paul Glavine in 2019.

Who are Helus Pharma's investors?

Helus Pharma's investors include Awareness Venture, Bailey Venture Partners, Innovating Capital, JLS, LifeSci Venture Partners, Noetic, O2h Ventures, Palo Santo VC and 1 more.

How much funding has Helus Pharma raised?

Helus Pharma has disclosed $218M raised across 10 of its 34 known rounds.

Where is Helus Pharma headquartered?

Helus Pharma is headquartered in Toronto, CA.

Helus Pharma

NASDAQ: HELP

Toronto, CA · Founded 2019 · 9 known investors

Find your way into Helus Pharma

Paths you didn't know you had: your email and LinkedIn already hold routes to the Helus Pharma team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Helus Pharma is a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions such as depression, anxiety, schizophrenia, and bipolar disorder. It focuses on advancing novel treatments for mental health disorders through clinical development and commercialization.

Biotech Digital Health Healthtech Mental Health

Founders & leadership

Helus Pharma was founded in 2019 by Eric So, John Kanakis, and Paul Glavine.

Eric SoCo-Founder, Executive ChairmanEric So is co-founder and executive chairman of Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions. He has held C-level roles in corporate strategy, development, and finance across public and private companies at various stages of growth.

John KanakisCo-FounderJohn Kanakis is co-founder of Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and neurological conditions. He brings approximately 25 years of experience across private and public companies, with a track record of founding multiple ventures in biotech, medtech, cleantech, AI, and cybersecurity sectors.

Paul GlavineCo-Founder and Chief Growth OfficerPaul Glavine is Co-Founder and Chief Growth Officer at Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions. He also serves as Chairman of the Board at LongPoint ETFs, a firm focused on Canadian ETF strategies.

Gabriel FahelExecutive

Douglas DrysdaleExecutive

Jacqueline PoriadjianExecutive

Michael HalsteadChief Executive OfficerMichael Halstead is Chief Executive Officer of Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies targeting psychiatric and CNS conditions including depression and anxiety.

Michael ColaChief Executive Officer

Aaron BartloneChief Operating OfficerAaron Bartlone is Chief Operating Officer of Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS disorders. He has extensive experience in product development, clinical trials, regulatory affairs, and commercialization across the biopharmaceutical industry, with involvement in nine new drug commercializations.

Lori ChallengerChief Compliance, Ethics & Administrative OfficerLori Challenger is Chief Compliance, Ethics & Administrative Officer at Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions. She brings over 20 years of experience in compliance, governance, organizational transformation, and people operations across startups, scale-ups, and publicly traded companies in regulated industries.

Amir InamdarChief Medical OfficerAmir Inamdar is a psychiatrist with over 20 years of experience in clinical research and drug development for psychiatric disorders. He has led clinical trial design and regulatory strategy for novel psychiatric therapeutics, including first-in-human, proof-of-concept, and pivotal studies.

Alex NivorozhkinChief Scientific OfficerAlex Nivorozhkin is Chief Scientific Officer of Helus Pharma, a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS disorders. He has held senior executive roles and contributed inventions in life sciences and pharmaceuticals.

Investors · 9

Awareness Venturelisted by Awareness VentureWestport

Bailey Venture Partnerslisted by Bailey Venture PartnersCoral Gables

Innovating Capitallisted by Innovating CapitalNew York · $10K – $3M

How we know: Innovating Capital's portfolio page · Not right? Tell us

JLSlisted by JLSNew York

LifeSci Venture Partnerslisted by LifeSci Venture PartnersNew York

How we know: LifeSci Venture Partners's portfolio page · Not right? Tell us

Noeticlisted by NoeticToronto

How we know: Noetic's portfolio page · Not right? Tell us

O2h Ventureslisted by O2h VenturesCambridge

How we know: O2h Ventures's portfolio page · Not right? Tell us

Palo Santo VClisted by Palo Santo VC

How we know: Palo Santo VC's portfolio page · Not right? Tell us

Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco

How we know: Pivotal Life Sciences's portfolio page · Not right? Tell us

Funding

SEC filings, press & company announcements

$218M disclosed across 10 of 34 rounds · 2020–2026

Undisclosed amountstock offeringJul 2026
Source ↗

▶$262KofferedSep 2026 · 4 investors · Other

Rule 506(b)